Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Olema Pharmaceuticals, Inc. - Common Stock (NQ: OLMA )

4.970 +0.140 (+2.90%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Olema Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 Next >
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Olema Oncology to Participate in Upcoming Investor Conferences
From Olema Oncology
Via GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference
From Olema Oncology
Via GlobeNewswire
Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium
From Olema Oncology
Via GlobeNewswire
Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor
From Olema Oncology
Via GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement
From Olema Oncology
Via GlobeNewswire
Olema Oncology to Present New Data Combining Palazestrant with Ribociclib at the San Antonio Breast Cancer Symposium
Olema will host an investor conference call at 8:00 a.m. ET on December 10, 2024 
From Olema Oncology
Via GlobeNewswire
Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Olema Oncology
Via GlobeNewswire
Olema Oncology to Participate in Upcoming Investor Conferences
From Olema Oncology
Via GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024
From Olema Oncology
Via GlobeNewswire
Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Poster presentations include new preclinical data demonstrating activity for palazestrant in combination with capivasertib and everolimus, and OP-3136, Olema’s KAT6 inhibitor, in combination with... 
From Olema Oncology
Via GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference
From Olema Oncology
Via GlobeNewswire
Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From Olema Oncology
Via GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Olema Oncology to Participate in Upcoming Investor Conferences in June
From Olema Oncology
Via GlobeNewswire
Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
From Olema Oncology
Via GlobeNewswire
Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Olema Oncology
Via GlobeNewswire
Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress
Olema will host an investor conference call at 8:00 a.m. ET on May 15, 2024 
From Olema Oncology
Via GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Olema Oncology to Participate in Upcoming Investor Conferences in May
From Olema Oncology
Via GlobeNewswire
Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
From Olema Oncology
Via GlobeNewswire
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
From Olema Oncology
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.